NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Thomas M Zollner on OCEANIC-STROKE Study: Amazingly Good News for Patients With Stroke
Thomas M Zollner/LinkedIn
Nov 24, 2025, 15:04

Thomas M Zollner on OCEANIC-STROKE Study: Amazingly Good News for Patients With Stroke

Thomas M Zollner, Reproductive Health Cluster Lead at Bayer, reposted from Alexander Krupp on LinkedIn:

”Amazingly good news for patients with stroke: The Phase III study OCEANIC-STROKE in secondary stroke prevention met its primary endpoint.

Asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared to placebo, both in combination with antiplatelet therapy, in patients after a non-cardioembolic ischemic stroke or high-risk ischemic attack.

OCEANIC-STROKE is the first successfully completed Phase III study of a FactorXIa Inhibitor.

Each year, approximately 12 million people worldwide will experience a stroke.

Of these, 20-30% will be a recurrent stroke.

Despite available secondary stroke prevention options, the risk of secondary stroke remains high.

One in five stroke survivors will have another stroke within five years.”

Quoting Alexander Krupp‘s post:

”A new medicine was born today: We are just announcing positive results of the OCEANIC STROKE study in secondary stroke prevention.

There a few moments in a worklife when you can be part of a novel medicine being born.

For me, this is today: We are bringing a novel treatment option to millions of patients to reduce the risk of secondary ischemic stroke.

I am humble and honored to be part of such an incredible TeamBayer that has just made the impossible possible, unlocking superpowers in a new operating model DSO.

Thank you!”

Stay updated with Hemostasis Today.

Alexander Krupp asundexian Bayer Health Hematology Hemostasis Hemostasis Today ischemic attack Medicine OCEANIC-STROKE stroke Thomas M Zollner thrombosis
NewsFeed